The UK and US have signed a landmark trade agreement that will maintain zero import taxes on UK pharmaceutical exports being sold in the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise spending on medicines through the public health system. This move ensures that import taxes on these key exports will stay at nothing for a period of the next three years.
This development follows earlier statements to hike duties on branded pharmaceutical imports, with increases discussed reaching 100%.
"This agreement with the United Kingdom reinforces the global environment for new treatments and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a release said.
Trade Impact
Medicines constitute one of the the United Kingdom's biggest exports to the US, which is by far the biggest market for leading UK drugmakers.
Statistics indicate that in the one-year period to the end of last September, the UK exported drugs worth over eleven billion pounds to the US. This amount made up 17.4% of British export trade in that span.
"This deal safeguards work, stimulates funding and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," a minister stated.
Specific UK Commitments
The deal entails several key pledges from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to double total health service expenditure on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The sum drug companies must refund to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds exceeded 20%.
Industry Background
The pact takes place against a protracted dispute between the pharmaceutical industry and the British authorities over spending levels and approval rates.
The disagreement were exacerbated by assertions that American consumers were paying several times more for the same drugs than people in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been directed toward American operations.
One official acknowledged that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had declined as a proportion of its total funding over the previous ten-year period.
